Navigation Links
Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference
Date:11/21/2013

is.  This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  While FDA clearance is being sought, an initial launch for the APPY1 Test is ongoing in select European countries.  For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for the APPY1 Test required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively m
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Venaxis APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
2. Venaxis Announces Pricing of Offering of Common Stock and Warrants
3. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
4. Dyadic International To Present At Two Major Conferences In December 2013
5. Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting
6. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
7. Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
8. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
9. Accuray to Present at Piper Jaffray 25th Annual Healthcare Conference
10. Cartes 2013: DERMALOG Presents World Firsts in Biometrics
11. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 , Not for release, ... or from any jurisdiction where to do so would constitute ... Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ...  Shire confirms it has held a meeting with representatives of ... without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... 2014 Product and process impurities ... abundance and are often “lost in the noise,” ... Join presenters Dr. Rowel Tobias, Senior Scientist, Protein ... Head of Quality at Nanotherapeutics, Inc., to lear ... speed detection and quantitation while achieving the required ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... Fusion Platform Includes Innovative Biometric ... ... 12 WCC Smart Search & Match,a leading provider of ... Systems, a leader in providing,innovative eye biometric technology for identification ...
... Throughout a ... Product,s Lifecycle, NEW YORK, Feb. ... an industry leader in patient,enrollment for clinical trials, will join the ... this partnership, Ketchum,will greatly expand the depth of services offered to ...
... (NYSE: BMY ) today announced that the company,s ... the Board. Mr. Cornelius, who,was named chief executive officer ... well. Mr. Cornelius, current employment contract, which,expires in May ... B.,Campbell, chairman, president and CEO, Textron Inc., as lead ...
Cached Biology Technology:WCC Smart Search & Match and Retica Announce Global Collaboration 2Ketchum Joins Forces with Clinical Trial Recruitment Agency MMG 2Ketchum Joins Forces with Clinical Trial Recruitment Agency MMG 3Ketchum Joins Forces with Clinical Trial Recruitment Agency MMG 4Bristol-Myers Squibb Board Elects James M. Cornelius Chairman of the Board 2
(Date:7/11/2014)... Tenn., July 11, 2014--Researchers at the Department of ... R&D 100 awards, presented by R&D Magazine in ... , "These awards recognize the tremendous value of ... Moniz. "Research and development at the National Labs ... challenges and pursue the scientific and technological innovations ...
(Date:7/11/2014)... . X-ray ... of X-rays through a specimen instead of attenuation resulting ... often of much higher quality than those based on ... Pfeiffer are particularly interested in developing new approaches for ... imaging. One main goal is to make this method ...
(Date:7/11/2014)... Social animals often develop relationships with other group members ... In wild chacma baboons the strategy for grooming activities ... are just published in the scientific journal Biology ... of baboons is not practiced without ulterior motives. To ... for the individual, while grooming another individual can provide ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... in German . There are many ... But how can the chemical properties of a material be ... of Technology developed a method to attach molecules at exactly ... can allow the positioning of chemical signals, telling living cells ...
... benefits of breast milk have long been appreciated, but ... a unique property that makes mother,s milk better than ... The finding, published in the August issue of ... explains how breast milk, but not infant formula, fosters ...
... it out to regulate gene expression on the DNA ... enzymes that transcribe DNA into RNA. Their repressor opponents ... coil around histone proteins, an amalgam called chromatin, effectively ... RNA strand. Both teams maneuver by chemically modifying ...
Cached Biology News:The laser beam as a '3-D painter' 2Breast milk promotes a different gut flora growth than infant formulas 2Breast milk promotes a different gut flora growth than infant formulas 3Controlling gene expression: How chromatin remodelers block a histone pass 2Controlling gene expression: How chromatin remodelers block a histone pass 3
... J. Davison and Richard ... Contents include: information on ... paramyxoviruses, influenza and immunodeficiency ... analysis of viral NA ...
...
...
...
Biology Products: